Ratio Therapeutics raised $70 million for its radiopharmaceutical trial program, according to the reported Series C terms. The funding includes participation from existing investors Duquesne Family Office and Bristol Myers Squibb, alongside new backers. The capital injection is targeted at advancing radiopharma clinical development, a category where timelines and manufacturing capacity can determine trial feasibility and subsequent partnering leverage. For Ratio, the Series C reinforces momentum after earlier pipeline and platform-building work that depends on continued execution across dosing, imaging, and trial enrollment. The funding also indicates that large pharma remains willing to fund radiopharmaceutical risk as competition intensifies across imaging and targeted radionuclide strategies.